Minerco Inc. (MINE): TD Ameritrade sending out emails that pe...

Home > Boards > US OTC > Medical - Psychedelics > Minerco Inc. (MINE)

Followed By	23
Posts	4033
Boards Moderated	0
Alias Born	07/09/2014

2obee1

Tuesday, July 13, 2021 4:54:05 PM

Re: jimtash post# 346359

TD Ameritrade sending out emails that penny's like MINE won't be tradeable after Aug 13.

Dude, you're grasping at straws. I'd love to see an honest assessment from you in regard to just 2 of Jenge's lies.

Do you have the smarts to complete this request?

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Follow Board

Keyboard Shortcuts

Report TOS Violation

Molecular Data Inc. Announces ADS Ratio Change
Mullen Announces Hiring of Richard Curtis to President of International Operations
Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE MultiStem Ischemic Stroke Study
Ross Stores Down Over 21%, on Track for Largest Percent Decrease Since December 1993 -- Data Talk
Deere & Company Down Over 10%, on Pace for Largest Percent Decrease Since March 2020 -- Data Talk
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Macellum Issues Statement Regarding the Kohl’s Board’s Apparent Breach of Fiduciary Duty and Failure to Disclose Material Information Prior to 2022 Annual Meeting
Jakubowitz Law Reminds Upstart Shareholders of a Lead Plaintiff Deadline of July 12, 2022
Richemont Shares Fall After Fiscal Year Operating Profit Missed Views, No Resolution Regarding YNAP
Genius Group Acquires E-Squared Education Enterprises Furthering their Global Entrepreneur Education Vision
BIT Mining Limited to Report First Quarter 2022 Financial Results on May 27, 2022
BAE Systems’ New CV90 Combat Support Vehicles Delivered to Norway
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
SEC Fines Wells Fargo Broker $7 Million Over Suspicious Activity Reporting
Foghorn Therapeutics Shares Down After FDA Partial Clinical Hold
Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering
Bank of America Announces 2023 Financial Reporting Dates
AMD Chair and CEO Dr. Lisa Su to Keynote at COMPUTEX 2022
ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study
Top Company News of the Day

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Quotes:

IHub:

Detailed Quote